Alfred Garfall

1 month ago | nature.com | Oren Pasvolsky |Lei Feng |James Davis |Aimaz Afrough |Mariola Vazquez-Martinez |Utkarsh Goel | +22 more

AbstractTeclistamab, a BCMA-directed bispecific antibody, received regulatory approval for relapsed/refractory multiple myeloma (RRMM) based on the MajesTEC-1 study. Despite the fact that myeloma is primarily a cancer of elderly adults, only 15% of MajesTEC-1 participants (n = 24) were ≥75 years old. In this multicenter retrospective study, we report real-world outcomes of a large cohort of older RRMM patients treated with teclistamab.

2 months ago | targetedonc.com | Jordyn Sava |Alfred Garfall

In this episode of Targeted Talks, Alfred L. Garfall, MD, director of Autologous Hematopoietic Stem Cell Transplantation and section chief of Myeloma and Hematology-Oncology at Penn Medicine, discusses the phase 2 BMT CTN 1902 trial (NCT05032820) of idecabtagene vicleucel (ide-cel; Abecma), a study focused on patients with multiple myeloma who had a suboptimal response to first-line therapy, including autologous hematopoietic cell transplant and lenalidomide (Revlimid) maintenance.

Feb 26, 2025 | cgtlive.com | Alfred Garfall |Noah Stansfield

At the 2025 Tandem Meetings |Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR, held in Honolulu, Hawaii, February 12 to 15, 2025, interim data were presented from the phase 2 BMT CTN 1902 clinical trial (NCT05032820), which is evaluating Bristol Myers Squibb and 2seventy bio's idecabtagene vicleucel (ide-cel, marketed as Abecma), an FDA-approved chimeric antigen receptor T-cell (CAR-T) therapy, for the treatment of patients with multiple myeloma (MM) who had a suboptimal...

Oct 20, 2024 | nature.com | Nizar Bahlis |Luciano Costa |Maria-Victoria Mateos |Ajay K. Nooka |Aurore Perrot |Alfred Garfall | +1 more

Dear Editor,The risk of infection in patients with multiple myeloma (MM) is high, particularly for those with relapsed/refractory MM (RRMM), who typically exhibit substantial immune dysfunction due to multiple prior therapies as well as MM itself [1, 2]. The recent COVID-19 pandemic had an impact on patients with MM compared with non-MM patients, including a higher risk of infection, a higher excess mortality rate, and decreased survival in 2020 compared with 2019 [3].

Jul 24, 2024 | ajmc.com | Alfred Garfall

OpinionVideoJuly 24, 2024Author(s):Alfred L. Garfall, MD, discusses his hopes for the future treatment landscape of multiple myeloma. Video content above is prompted by the following questions:Please discuss any other data in multiple myeloma released at ASCO 2024 that you find noteworthy to share with colleagues. Outside of ASCO 2024, what ongoing research efforts are you most excited for in the treatment and management of multiple myeloma?